natgillin/translations-raw huggingface dataset:
FIG. 3 shows the structure of fast cut-off circuit 4 interposed between the output of microprocessor 6 a and demultiplexer circuit 12 a of first circuit section 1 a. 
Slika 3 prikazuje strukturu komunikacijskog kruga brzog prekidanja 4, umetnutog između izlaza mikroprocesora 6a i demultipleksnog komunikacijskog kruga 12a prve sekcije komunikacijskih krugova la.
Precipitate thus obtained is filtered and washed with water followed by 10% methanol in diethyl ether and dried under vacuum to get 2-methyl-2-[4-(4-nonylbenzylamino)-but-2-ynyl]malonic acid hydrochloride. 
Tako nastali talog se filtira, te ispere vodom, a zatim s 10 % metanola u dietil-eteru, te osuši u vakuumu kako bi se dobilo hidroklorid 2-metil-2-[4-(4-nonilbenzilamino)-but-2-iniljmalonske kiseline.
23:44–51, 1983) or to membranes from cells expressing cloned receptors as described below. 
Pharmacol., 23:44-51, (1983.)) ili na membrane iz stanica koje eksprimiraju klonirane receptore, kao što je opisano niže.
The compound of paragraph 1 having a structure selected from the group consisting of: or a pharmaceutically acceptable salt or prodrug thereof. 
Spoj prema zahtjevu 1, naznačen time da ima strukturu izabranu iz skupine koja se sastoji od: HR P20151425 T1 NH N
The monolithic intravaginal ring of claim 1, wherein the progesterone is homogeneously dispersed in the polysiloxane elastomer, preferably wherein the polysiloxane elastomer is a diorganopolysiloxane elastomer, more preferably dimethylpolysiloxane elastomer. 
Monolitni intravaginalni prsten u skladu s patentnim zahtjevom 1, naznačen time, da je progesteron homogeno raspršen u polisiloksan elastomeru, a polisiloksan elastomer po mogućnosti je diorganopolisiloksan elastomer ili čak dimetilpolisiloksan elastomer.
A composition comprising the AvPAL variant of any one of claims 1 to 6 for use in treating a pregnant female having hyperphenylalaninemia (HPA), wherein the composition is prepared to be administered in combination with a protein-restricted diet, wherein the combined administration of the composition and protein-restricted diet is effective to lower the phenylalanine concentration in the plasma of said female as compared to said concentration in the absence of administration of said combination. 
Pripravak, naznačen time, da sadržava varijantu AvPAL u skladu s bilo kojim od zahtjeva 1 do 6, za uporabu u liječenju trudnica s hiperfenilalaninemijom (HPA), koji se pripravlja za primjenu u kombinaciji s prehranom s ograničenim unosom proteina, pri čemu pripravak 1 dijeta s ograničenim unosom proteina učinkovito smanjuju koncentraciju fenilalanina u plazmi navedene ženske osobe u usporedbi s navedenom koncentracijom kada se navedeni pripravak ne primjenjuje
The immunogenic polypeptide of claim 1 or claim 2, wherein the E. coli AcfD (orf3526) protein has an amino acid sequence selected from the group consisting of SEQ ID NOs:1-19. 
Imunogenski polipeptid prema zahtjevu 1, naznačen time da E. coli AcfD (orf3526) protein ima amino kiselinsku sekvencu izabranu iz skupine koja se sastoji od SEQ ID Br. 1-19.
The construct for the use of claim 17, wherein the two initial doses are administered for 2, 3, 4, 5, 6, or 7 days or even longer. 
Konstrukt za uporabu prema zahtjevu 13, naznačen time što se dvije početne doze daju tijekom 1, 2, 3, 4, 5, 6, ili 7 dana ili čak i duže.
A process as claimed in claim 9 in which the water is heated to provide steam. 
Postupak prema zahtjevima 4 do 10 gdje se zagrijana tekućina zagrijava na temperaturu vrijednosti 85°C.
A hydrogen sulfate salt of Compound 1 according to claim 1 in anhydrous form. 
Sol hidrogen sulfata od Spoja 1 prema zahtjevu 1 u bezvodnom obliku.
“C3-C8-cycloalkyl” refers to a saturated carbocyclic group of from 3 to 8 carbon atoms having a single ring (e.g., cyclohexyl) or multiple condensed rings (e.g., norbornyl). 
"C,-Cg-cikloalkil" se odnosi na zasićenu karbocikličku skupinu s 3 do 8 atoma ugljika, s jednim prstenom (pr. cikloheksilna skupina) ili više međusobno spojenih prstenova (pr. norbonilna skupina).
A pharmaceutical composition comprising the antibody or antigen binding fragment thereof of claim 1 and a pharmaceutically acceptable carrier. 
Farmaceutska kompozicija koja sadrži antitijelo ili njegov antigen vezujući fragment iz bilo kojeg od patentnih zahtjeva 1-5, ili imunokonjugat iz bilo kojeg od patentnih zahtjeva 7-15 i farmaceutski prihvatljiv nosač.
A pharmaceutical composition that comprises the antibody or fragment of claim 1 in a human unit dose form. 
Farmaceutski sastav koji obuhvaća protutijelo ili fragment iz patentnog zahtjeva 1 u obliku ljudske jedinične doze.
The method of claim 1 or 2, wherein the proportion of impaired pixels in the hit frame, xl_i, is calculated based on the number of bytes of video lost due to the loss event i in the current hit frame, blp_i, divided by the number of lost and correctly received bytes in the current hit frame, bp, using the relation xl_i = blp_i / bp. 
Metoda prema zahtjevu 1 ili 2, naznačena time, da se udio oslabljenih piksela u zadanom okviru xl_i izračunava na temelju broja bitova videozapisa izgubljenih zbog događaja i gubitka u trenutnom zadanom okviru bip_i, podijeljen brojem izgubljenih i pravilno primljenih bitova u trenutnom zadanom okviru, bp, koristeći relaciju xl_1 = blp_i/bp.
The pharmaceutical composition for use as defined in any one of claims 1 to 3, wherein said antagonistic anti-human IL-13 antibody comprises a variable heavy chain region comprising complementarity determining regions CDRH1, CDRH2 and CDRH3 having the sequences of SEQ ID NO: 117, SEQ ID NO: 123, and SEQ ID NO: 135, respectively; and a variable light chain region comprising complementarity determining regions CDRL1, CDRL2 and CDRL3 having the sequences of SEQ ID NO: 99, SEQ ID NO: 104, and SEQ ID NO: 115, respectively. 
VL područje lanca, koje sadrži aminokiselinski slijed s formulom: FRL1-CDRL1-FRL2-CDRL2FRL3-CDRL3-FRL4, gdje se FRL1 sastoji od bilo kojeg od SEQ ID NO: 20 do 25; CDRL1 se sastoji od bilo kojeg od SEQ ID NO: 99 do 103; FRL2 se sastoji od SEQ ID NO: 29; CDRL2 se sastoji od bilo kojeg od SEQ ID NO: 104 do 114; FRL3 se sastoji od bilo kojeg od SEQ ID NO: 30 do 56; CDRL3 se sastoji od bilo kojeg od SEQ ID NO: 115 do 116; i FRL4 se sastoji od bilo kojeg od SEQ ID NO: 57 do 59; i
hydrolyzing said ester of the compound of formula (I) to produce said compound of formula (I) or a salt thereof. A process according to claim 1, wherein said residue A is selected from the group consisting of halide, phosphate, sulfate, nitrate, and organic carboxylate. 
16.Proizvodni postupak prema zahtjevu 15, naznačen time, da je navedeni ostatak A odabran iz skupine koju čine halid, fosfat, sulfat, nitrat i organski karboksilat, 17.Proizvodni postupak prema zahtjevu 16, naznačen time, da je navedeni ostatak A odabran iz skupine koju čine klorid, bromid 1 jodid.
The polypeptide according to claim 1, wherein the polypeptide binds to an IL-17F mutant with reduced affinity as compared to binding to the wildtype human IL-17F sequence, wherein the IL-17F mutant comprises one or more mutations of R47A, I86A, and N89A. 
Polipeptid prema bilo kojem od zahtjeva 1-5, naznačen time da se polipeptid specifično veže na ljudski IL-17 F, pri čemu se polipeptid veže na R47A i/ili R73A i/ili I86A i/ili N89A IL-17F mutant sa značajno smanjenim afinitetom u usporedbi s vezanjem na divlji tip IL-17F sekvence.
The therapeutic monoclonal antibody and the compound of formula I for use according to claim 1, wherein the subject has an FcYR polymorphism or a KRAS mutation, or wherein ii) the subject has previously been identified as being unresponsive to therapeutic antibody treatment, or wherein 
Terapijsko monoklonsko protutijelo i kemijski spoj iz formule I za uporabu u skladu s patentnim zahtjevom 1, gdje subjekt ima FcYR polimorfizam ili KRAS mutaciju, ili gdje je ii) prethodno utvrđeno da subjekt ne reagira na terapiju terapijskog protutijela, ili gdje iii) kod subjekta postoji oštećena funkcija stanične citotoksičnosti ovisne o protutijelu (ADCC).
Formulations as claimed in any one of claims 1 to 10, in the form of melt-in-the-mouth tablets, mouthwashes, gels to be dispersed in the oral cavity, chewing gums and the like. The use of: 
Formulacije kako su prijavljene u bilo kojem patentnom zahtjevu 1 do 10, naznačene time da su u obliku tableta koje se tale u ustima, vodica za usta, gelova koji se dispergiraju u usnu šupljinu, guma za žvakanje i slično.
Synthesis of the Compounds of the Invention 
Broj objave europskog patenta:
The composition according to any one of the preceding claims, wherein the carbon dioxide supercritical fluid extract of adlay bran (B) is extracted at a pressure of from about 150 bar to about 500 bar and a temperature of from about 30°C to about 80°C. 
Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se ekstrakt mekinja Jobovih suza suprakritičnim ugljičnom dioksidom (B) ekstrahira pod tlakom od otprilike 150 bar (15 MPa) do otprilike 500 bar (50 MPa) i na temperaturi od otprilike 30 °C do otprilike 80 °C.
A procedure to enhance the growth of crops, comprising the step of applying the fertilizer composition as claimed in any one of the above claims 1 to 8 to a plant at any of its stages of growth, or directly to the soil to be used for the crop. 
Postupak poboljšavanja rasta usjeva, naznačen time što se sastoji u koraku primjene gnojive smjese u skladu s bilo kojim od prethodnih patentnih zahtjeva 1 do 7 na biljci u bilo kojem od njezinih stadija rasta, ili izravno na tlo koje treba upotrijebiti za uzgoj usjeva.
is C(O)OR7 or C(O)NR8R9; R7, R8 and R9 are respectively and independently hydrogen, 5-6 membered heterocyclic group or C1-3alkyl, wherein R8 and R9, together with the nitrogen atom attached thereto, can form 5-6 membered heterocyclic group or oxo-5-6 membered heterocyclic group, said C1-3alkyl and 5-6 membered heterocyclic group can be optionally substituted by hydroxyl, C1-6alkyl, NR11R12, NR11S(O)qR10 or S(O)qR10; 
, R8 i R9 su respektivno i nezavisno vodik, 5-6 člana heterociklična skupina ili C1-3alkil, pri čemu R8 i R9, zajedno s atomom dušika koji je vezan na njih, mogu tvoriti 5-6 članu heterocikličnu skupinu ili okso-5-6 članu heterocikličnu skupinu, spomenuti C1-3alkil i 5-6 člana heterociklična skupina mogu izborno biti supstituirani hidroksilom, C1-6alkilom, NR11R12, NR11S(O)qR10 ili S(O)qR10;
The package according to claim 2, wherein said connector is fixed to a sealable tube which protrudes from an upper end of the casing. 
Pakiranje (100) u skladu s patentnim zahtjevom 2, naznačeno time što je navedeni priključak (11) fiksiran na brtvenu cijev (50) koja strši iz gornjeg kraja kućišta (2).
Dosage form for use according to claim 11, wherein the dosage form comprises a single dosing unit or two dosing units, dependent on whether said amount is provided by administration to one nostril or by administration to two nostrils, and is for single use or wherein the dosage form comprises at least two dosing units, preferably at least three dosing units, more preferably at least four dosing units and most preferably at least five dosing units and is for multiple uses. 
Oblik doziranja za uporabu prema zahtjevu 11, naznačen time da oblik doziranja sadrži jednu jedinicu za doziranje ili dvije jedinice za doziranje, d ovisno o tome da li je navedena količina predviđena za primjenu na jednu nosnicu ili za primjenu na dvije nosnice, te je za jednu primjenu ili pri čemu oblik doziranja sadrži najmanje dvije jedinice za doziranje, poželjno barem tri jedinice za doziranje, poželjnije barem četiri jedinice za doziranje i najpoželjnije najmanje jedinica za doziranje i za višestruke primjene.
The compound or pharmaceutically acceptable salt thereof of any of the preceding claims, wherein any atom not designated as deuterium is present at its natural isotopic abundance. 
Spoj ili njegova farmaceutski prihvatljiva sol za primjenu prema patentnom zahtjevu 1, gdje je bilo koji atom koji nije označen kao deuterij, prisutan kao izotop koji je najčešći u prirodi.
coupling the Har and Mpa residues of the compound of formula II, thereby forming a compound of formula III: and 
5 (IN kopuliranje Har i Mpa ostataka spoja formule II, da na taj način nastane spoj formule III:
The filtrate was used in step E. A small amount of diacid 10 was isolated before dilution, by filtering the suspension and washing the precipitate successively with an excess of water, acetone and ether. 
Filtrat se upotrijebi u koraku E. Mala količina dikiseline 10 se izolira prije razrjedenja, filtracijom suspenzije i pranjem precipitata sukcesivno sa suviškom vode, acetona i etera.
reacting the compound of the Formula X with formic acid and formaldehyde or a polymer of formaldehyde to form a formic acid salt of ZD6474; adding an inert organic solvent and a suitable base so as to form the free base of ZD6474; whereafter the ZD6474 obtained in the form of the free base may be converted into a pharmaceutically acceptable salt, if necessary. 
(n) reakciju spoja formule X sa mravljom kiselinom i formaldehidom ili sa polimerom formaldehida sa svrhom nastajanja soli mravlje kiseline ZD6474; (0) dodavanje inertnog organskog otapala i prikladne baze sa svrhom nastajanja slobodne baze ZD6474; gdje ZD6474, dobiven u obliku slobodne baze, može biti pretvoren u farmaceutski prihvatljivu sol, ako je potrebno.
Thus, in one aspect there is provided the polymorph in isolated form. 
Prema tome, u jednom aspektu osigurava se polimorf u izdvojenom obliku.
Enteric Polymer Dispersion 30% 3 
Disperzija kopolimera metakrilne kiseline 30 % *
A method for treating acute exacerbation of psychosis in a patient having psychosis, comprising co-administering a compound of formula (I): 
(D ili njegove farmaceutski prihvatljive soli, te antipsihotičkog sredstva, naznačena time da je za uporabu kod liječenja akutnog pogoršanja psihoze kod pacijenta koji ima psihozu.
The suspension formulation comprised of the following: 
Broj objave europskog patenta:
Also preferably, reaction with trimethylchlorosilane in a suitable solvent may be used for the preparation of the hydrochloride addition salt. Preferably a compound of general formula (I) can be obtained by (a') reacting a compound of general formula (V), wherein R represents methyl, benzyl or tetrahydropyranyl with dimethylamine hydrochloride and paraformaldehyde in an inert reaction medium under Mannich conditions and 
(a') reagiranje spoja opće formule (V), gdje R predstavlja -C;.g-alkil, -C3.g-cikloalkil, -Ci.3-alkilen-fenil, -C,.3-alkilen-naftl, tetrahidropiranil ili -C(=0)-C,4-alkil, sa dimetilamin klorovodikom i paraformaldehidom u inertnom reakcijskom mediju pri Manmnichovim uvjetima i
BscP, denoting the bitrate of P frames computed per scene; 
BE, koji označuje brzinu bitova P kadrova izračunatih po sceni;
Nickmilder et. al. identified a 3,4 and 5,6 dihydrodiol rapamycin metabolite in rat liver microsomes. 
Nickmilder i sur. identificirali su 3,4 i 5,6-dihidrodiolni metabolit rapamicina u mikrosomima jetre štakora.
Mineral materials suitable for the use in the process according to the present invention are preferably selected from the group comprising natural calcium carbonate (GCC) such as marble, chalk, limestone; precipitated calcium carbonate (PCC) such as aragonitic PCC, vateritic PCC and/or calcitic PCC, especially prismatic, rhombohedral or scalenohedral PCC; surface modified calcium carbonate; dolomite; talc; bentonite; clay; magnesite; satin white; sepiolite, huntite, diatomite; silicates; and mixtures thereof. 
- konačni udio krutih tvari u vodenoj suspenziji dobiven nakon koraka d) je od 80 do 85 % tež.. Postupak prema zahtjevu 1, naznačen time da je najmanje jedan mineralni materijal odabran iz skupine koja sadrži prirodni kalcijev karbonat (GCC) kao što je mramor, kreda, vapnenac; nataloženi kalcijev karbonat (PCC) kao što je aragonitni PCC, vateritni PCC iili kalcini PCC, naročito prizmatični, tomboedarski ili skalenoedarski PCC; površinski modificirani kalcijev karbonat; dolomit; talk; bentonit; glina; magnezit, svileno bijeli; sepiolit, huntit, dijatomit; silikati; i njihove mješavine.
Use according to any one of claims 1 to 5, wherein the metallic nanoparticle is essentially spherical or ovoid in shape. 
Uporaba u skladu s patentnim zahtjevom 1 ili farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 2, pri čemu je nanočestica u osnovi sferičnog ili ovalnog oblika.
The solid oral extended release pharmaceutical dosage form of anyone of claims 1, 3, 5 and 7, wherein the extended release matrix formulation after having been stored at 25 °C and 60 % relative humidity (RH) for at least 1 month provides a dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C, characterized by the percent amount of active agent released at 1, 4 and 12 hours of dissolution that deviates no more than about 15 % points from the corresponding in-vitro dissolution rate of a reference formulation prior to storage. 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema bilo kojem od zahtjeva 1 do pri čemu formulacija matrice sa produljenim otpuštanjem nakon što je pohranjena na 25 *C 1 60 % relativne vlažnosti (RH) tijekom najmanje 1 mjeseca daje brzinu otapanja, koja kada je mjerena na USP aparatu 1 (košara) kod 100 okr/min. u 900 ml simulirane želučane tekućine bez enzima (SGF) na 37? C, naznačen time da postotak količine oslobođenog aktivnog sredstva kod 1,4 1 12 sati otapanja nema odstupanje veće od oko 15 % točaka u odnosu na odgovarajuću in-vitro brzinu otapanja referentne formulacije prije skladištenja.
Y is -(C3-C8)-cycloalkyl, in which cycloalkyl is unsubstituted or substituted independently of one another once, twice or three times by R1, or the radical of the formula III -A3-A5 (III) 
O oO-z gdje Y je (C:3-Cg)-cikloalkil, gdje cikloalkil nije supstituiran ili je međusobno neovisno mono-, di- ili trisupstituiran s RI, ili radikal formule III
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidenebenzonorbornene-5-yl)amide and as component (B) bixafen. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) ciprodinil.
A binding molecule according to claim 1, characterized in that the binding molecule is human. 
Molekula za vezanje u skladu s patentnim zahtjevom 1, naznačena time, da je molekula za vezanje ljudska molekula.
The seasonal thermal energy storage system for cold and heat supply of claim 6, characterized in that the user terminal is a low temperature ground radiant panel. 
Sustav sezonske pohrane toplinske energije za dovođenje rashladnog i toplinskog učina prema zahtjevu 2, naznačen time što korisnički terminal (5) je nisko temperaturna podna ploča za zračenje.
PRIOR ART Stable thyroid hormone preparations in form of tablets are already disclosed in the prior art, e.g. 
Stabilni pripravci koji sadrže tiroidne hormone u obliku tableta već su obuhvaćeni stanjem tehnike, npr.
adding a first reagent to the fluid sample, wherein the first reagent is an oxidising agent being reactive with the treatment chemical to produce a first product, wherein the first product is an aldehyde; 
dodavanje prvog vodenog reagensa u uzorak fluida, prvi vodeni reagens reagira s kemikalijom za obradu da se dobije prvi proizvod;
comparison of a sequence of received symbols of each packet with a corresponding sequence of expected symbols for the same packet; and 
- < uspoređivanje sekvence zaprimljenih simbola (a,') svakog paketa s odgovarajućom sekvencom očekivanog simbola (a,) istog paketa; i
Method according to anyone of claims 1 to 4, wherein the concentrator (C) transmits a number (L) of storage locations to the remote meter (RM) requesting transmission of said periodically measured and stored consumption related data stored in respective L storage locations at the remote meter (RM). 
Metoda prema bilo kojem od patentnih zahtjeva 1 do 4, pri čemu sabirnik (C) prenosi broj (L) lokacija za pohranu u daljinski brojač (RM) zahtijevajući prijenos navedenih periodički izmjerenih 1 pohranjenih podataka vezanih uz potrošnju na svakoj od L lokacija za pohranu u daljinskom brojaču (RM).
the composition is free of mammalian proteins other than said mature elastase protein; 
(1i) farmaceutski sastav je bez proteina sisara, osim spomenute zrele protein elastaze;
A method of taste masking a fluoroquinolone selected from levofloxacin or ofloxacin, comprising complexing the fluoroquinolone with a divalent or trivalent cation. 
Postupak maskiranja okusa fluorokinolona izabranog iz levofloksacina ili ofloksacina, obuhvaća spravljanje kompleksa fluorokinolona s dvovalentnim ili trovalentnim kationom.
A compound of the formula (I) 
Spoj formule (1) gdje
Process according to Claim 1, in which the surface of the frozen or deep-frozen food comprises more than two support points, alternating with two or more arches. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da površina smrznutog ili duboko smrznutog prehrambenog proizvoda sadržava više od dvije potporne točke, naizmjence s dva ili više lukova.
A method for the treatment of a disease related to 5-HT6 receptor where said disease is Parkinson's disease, comprising the step of administering to a patient in need thereof an effective amount of a compound according to claim 3 . 
Spoj formule (D) sukladno patentnom zahtjevu 1, za proizvodnju lijeka za liječenje poremećaja središnjeg živčanog sustava povezanog s ili pogođenog s 5-HT4 receptorima. HR P20190446 T1 14.
pharmaceutically-acceptable salts thereof. A method of enhancing motility of the gastrointestinal tract in a mammal, the method comprising administering to the mammal a pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a compound of formula (I): 
Add oc i (€) po izboru uklanjanje zaštitne skupine ili skupina iz R", čime se dobiva spoj formule (I) ili njegova farmaceutski prihvatljiva sol, solvat ili zaštićeni derivat.
selectively reacting the 3'-amino group with a first protecting group consisting of an acid-labile group; reacting the 5'-hydroxyl group with a second protecting group consisting of acyl, base-labile trialkyl silyl ether, or fluoride-labile silyl ether; and 
reakcija navedene 5’-hidroksil-skupine s drugom zaštitnom skupinom koja se sastoji od sljedećih: acil, bazično labilni trialkilsilileter, ili fluoridno labilni silileter; i reakcija navedene nukleozidne baze s trećom zaštitnom skupinom koja je acil-skupina ili formamidinil-skupina;
The compound for use as claimed in any one of the preceding claims wherein the compound is administrated in a daily dosage range selected from 1 mg to 500 mg given singly or in multiple divided dosage, preferably in the range of 4 mg to 250 mg given singly or in multiple divided dosage, especially in the range of 4 mg to 50 mg. 
Spoj za uporabu prema bilo kojem od prethodnih zahtjeva gdje se spoj primjenjuje u dnevnoj dozi izabranoj u rasponu od 1 mg do 500 mg bilo u pojedinačnoj dozi ili u više podijeljenih doza, poželjno u rasponu od 4 mg do 250 mg bilo u pojedinačnoj dozi ili u više podijeljenih doza, posebno u rasponu od 4 mg do 50 mg.
sulfobutyl ethers of a-cyclodextrin, B-cyclodextrin, and Y-cyclodextrin. A pharmaceutical composition according to claim 1, wherein said cyclodextrin is hydroxypropyl-B-cyclodextrin. A pharmaceutical composition according to claim 1, wherein the molar ratio of cyclodextrin to said HDAC inhibitor is from 0.5 to 5. 
Farmaceutski sastav prema bilo kojem zahtjevu od 1 do 8, naznačen time, da nadalje sadrži dodatne farmaceutski prihvatljive sastojke. Farmaceutski sastav prema bilo kojem zahtjevu od 1 do 9, naznačen time, da je sterilan i oslobođen od pirogena.